Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
phosphodiesterase/infarci
Le lien est enregistré dans le presse-papiers
15 résultats
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The field relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The field further relates to inhibitors of
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3',5'-monophosphate specific
Method of treating myocardial infarction with PDE-5 inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention generally relates to the prevention of ischemia/reperfusion injury. In particular, the invention provides a method of preventing ischemia/reperfusion injury by administering a phosphodiesterase-5 (PDE5) inhibitor such as
Substituted N-arylmethyl and heterocylylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
(a) Field of the Invention
The invention relates to substituted N-arylmethyl and heterocyclylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines, to pharmaceutical compositions containing them and to methods for a) effecting c-GMP-phosphodiesterase inhibition, b) treating heart
Uses
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The field relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The field further relates to inhibitors of
4-(or 5-) substituted catechol derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to 4-substituted or 5-substituted catechol derivatives that are useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of
Organic compounds
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue or in vascular smooth muscle). The invention
Organic compounds
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue or in vascular smooth muscle). The invention
Organic compounds
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue or in vascular smooth muscle). The invention
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The field relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (neutral endopeptidase or NEP) useful for the treatment of certain cardiovascular diseases and related disorders, e.g., hypertension, congestive heart disease, and
Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to the use of the dye methylene blue (MB) or a related compound to prevent or reverse an exaggerated hemodynamic reaction in animals in need thereof, including humans. More specifically, the present invention concerns the use of MB or a related
Carbostyril derivative
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to a novel carbostyril derivative and its salts, having excellent platelet aggregation inhibitory effect, calcium antagonism, hypotensive effect and phosphodiesterase inhibitory effect, processes for preparing the same and a pharmaceutical composition containing the
Fused pyridazine compounds
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to a novel fused pyridazine compound. In particular, the present invention relates to a novel fused pyridazine compound which is useful as drug.
DESCRIPTION OF RELATED BACKGROUND ART
Recently, studies on compounds exhibiting inhibitory activity
Carbostyril derivative
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD
The present invention relates to a novel carbostyril derivative, a salt thereof, a process for producing said derivative, and a pharmaceutical composition for inhibiting platelet aggregation which contains said novel carbostyril derivative as an active ingredient.
BACKGROUND OF THE
Combinations
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
COMBINATIONS
The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one active ingredient selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
